<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p6" style="overflow: hidden; position: relative; background-color: white; width: 1286px; height: 909px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_6{left:89px;bottom:23px;letter-spacing:-0.46px;word-spacing:0.13px;}
#t2_6{left:352px;bottom:29px;}
#t3_6{left:359px;bottom:23px;letter-spacing:-0.03px;}
#t4_6{left:391px;bottom:29px;}
#t5_6{left:396px;bottom:23px;letter-spacing:-0.27px;word-spacing:-0.21px;}
#t6_6{left:558px;bottom:29px;}
#t7_6{left:565px;bottom:23px;letter-spacing:-0.39px;word-spacing:-0.09px;}
#t8_6{left:335px;bottom:836px;letter-spacing:0.22px;word-spacing:-0.51px;}
#t9_6{left:335px;bottom:806px;letter-spacing:0.38px;word-spacing:-0.68px;}
#ta_6{left:1139px;bottom:25px;letter-spacing:-0.05px;}
#tb_6{left:89px;bottom:755px;letter-spacing:-0.15px;word-spacing:-0.1px;}
#tc_6{left:89px;bottom:733px;letter-spacing:-0.07px;word-spacing:-1.03px;}
#td_6{left:89px;bottom:710px;letter-spacing:-0.12px;word-spacing:0.1px;}
#te_6{left:546px;bottom:710px;letter-spacing:-0.17px;}
#tf_6{left:89px;bottom:688px;letter-spacing:-0.05px;word-spacing:0.01px;}
#tg_6{left:430px;bottom:688px;letter-spacing:-0.23px;}
#th_6{left:448px;bottom:688px;}
#ti_6{left:89px;bottom:665px;letter-spacing:-0.1px;}
#tj_6{left:233px;bottom:665px;letter-spacing:-0.13px;word-spacing:-0.34px;}
#tk_6{left:89px;bottom:627px;letter-spacing:-0.18px;word-spacing:-1.05px;}
#tl_6{left:89px;bottom:604px;letter-spacing:-0.08px;word-spacing:0.07px;}
#tm_6{left:89px;bottom:582px;letter-spacing:-0.04px;word-spacing:0.01px;}
#tn_6{left:89px;bottom:559px;letter-spacing:-0.16px;word-spacing:0.13px;}
#to_6{left:521px;bottom:567px;letter-spacing:-0.17px;}
#tp_6{left:543px;bottom:559px;letter-spacing:0.21px;word-spacing:-0.21px;}
#tq_6{left:89px;bottom:537px;letter-spacing:-0.14px;word-spacing:-0.95px;}
#tr_6{left:89px;bottom:514px;letter-spacing:-0.15px;word-spacing:0.13px;}
#ts_6{left:511px;bottom:521px;letter-spacing:-0.17px;}
#tt_6{left:529px;bottom:514px;letter-spacing:-0.19px;word-spacing:0.18px;}
#tu_6{left:89px;bottom:491px;letter-spacing:-0.19px;word-spacing:0.17px;}
#tv_6{left:89px;bottom:469px;letter-spacing:0.01px;}
#tw_6{left:159px;bottom:476px;letter-spacing:-0.04px;}
#tx_6{left:225px;bottom:469px;letter-spacing:0.07px;}
#ty_6{left:263px;bottom:469px;word-spacing:-0.02px;}
#tz_6{left:478px;bottom:469px;letter-spacing:-0.53px;}
#t10_6{left:510px;bottom:469px;letter-spacing:0.02px;word-spacing:-0.04px;}
#t11_6{left:89px;bottom:446px;letter-spacing:-0.02px;word-spacing:-1.21px;}
#t12_6{left:236px;bottom:446px;letter-spacing:-0.16px;word-spacing:-0.62px;}
#t13_6{left:89px;bottom:407px;letter-spacing:-0.11px;word-spacing:0.09px;}
#t14_6{left:89px;bottom:384px;letter-spacing:-0.16px;word-spacing:0.14px;}
#t15_6{left:89px;bottom:362px;letter-spacing:-0.1px;word-spacing:0.07px;}
#t16_6{left:89px;bottom:339px;letter-spacing:-0.12px;word-spacing:0.09px;}
#t17_6{left:376px;bottom:347px;letter-spacing:-0.17px;}
#t18_6{left:398px;bottom:339px;letter-spacing:0.07px;}
#t19_6{left:436px;bottom:339px;letter-spacing:-0.01px;}
#t1a_6{left:89px;bottom:317px;letter-spacing:0.02px;}
#t1b_6{left:149px;bottom:317px;letter-spacing:-0.08px;word-spacing:-1.13px;}
#t1c_6{left:402px;bottom:317px;letter-spacing:-0.49px;}
#t1d_6{left:432px;bottom:317px;letter-spacing:-0.12px;word-spacing:-1.09px;}
#t1e_6{left:588px;bottom:317px;word-spacing:-1.19px;}
#t1f_6{left:89px;bottom:294px;letter-spacing:-0.12px;word-spacing:-0.86px;}
#t1g_6{left:89px;bottom:271px;letter-spacing:-0.12px;word-spacing:0.09px;}
#t1h_6{left:89px;bottom:249px;letter-spacing:-0.08px;word-spacing:0.07px;}
#t1i_6{left:89px;bottom:226px;letter-spacing:-0.2px;word-spacing:0.17px;}
#t1j_6{left:89px;bottom:204px;letter-spacing:0.03px;}
#t1k_6{left:164px;bottom:211px;letter-spacing:-0.06px;}
#t1l_6{left:89px;bottom:167px;letter-spacing:0.17px;word-spacing:0.51px;}
#t1m_6{left:89px;bottom:143px;letter-spacing:-0.07px;word-spacing:0.05px;}
#t1n_6{left:497px;bottom:143px;letter-spacing:0.02px;word-spacing:-0.02px;}
#t1o_6{left:89px;bottom:120px;letter-spacing:-0.03px;}
#t1p_6{left:442px;bottom:120px;letter-spacing:-0.53px;}
#t1q_6{left:474px;bottom:120px;letter-spacing:0.02px;word-spacing:-0.04px;}
#t1r_6{left:89px;bottom:98px;letter-spacing:-0.02px;}
#t1s_6{left:483px;bottom:98px;letter-spacing:-0.13px;word-spacing:0.1px;}
#t1t_6{left:89px;bottom:75px;letter-spacing:-0.09px;word-spacing:-0.7px;}
#t1u_6{left:89px;bottom:53px;letter-spacing:-0.04px;word-spacing:0.02px;}
#t1v_6{left:656px;bottom:755px;word-spacing:-0.01px;}
#t1w_6{left:656px;bottom:733px;letter-spacing:-0.07px;word-spacing:0.06px;}
#t1x_6{left:656px;bottom:710px;letter-spacing:-0.14px;word-spacing:0.12px;}
#t1y_6{left:656px;bottom:688px;letter-spacing:-0.12px;word-spacing:-0.26px;}
#t1z_6{left:656px;bottom:665px;letter-spacing:-0.04px;}
#t20_6{left:755px;bottom:665px;}
#t21_6{left:770px;bottom:665px;letter-spacing:-0.05px;word-spacing:0.04px;}
#t22_6{left:656px;bottom:642px;letter-spacing:-0.22px;}
#t23_6{left:705px;bottom:650px;letter-spacing:-0.17px;}
#t24_6{left:726px;bottom:642px;letter-spacing:-0.18px;word-spacing:-0.78px;}
#t25_6{left:656px;bottom:620px;letter-spacing:-0.09px;word-spacing:-0.46px;}
#t26_6{left:656px;bottom:597px;letter-spacing:-0.1px;word-spacing:0.08px;}
#t27_6{left:748px;bottom:605px;letter-spacing:-0.17px;}
#t28_6{left:656px;bottom:559px;letter-spacing:0.07px;}
#t29_6{left:656px;bottom:531px;letter-spacing:-0.11px;word-spacing:0.08px;}
#t2a_6{left:656px;bottom:508px;letter-spacing:-0.16px;word-spacing:-1.09px;}
#t2b_6{left:875px;bottom:508px;letter-spacing:-0.1px;word-spacing:-0.28px;}
#t2c_6{left:656px;bottom:485px;letter-spacing:-0.07px;word-spacing:0.04px;}
#t2d_6{left:656px;bottom:463px;letter-spacing:-0.17px;word-spacing:0.14px;}
#t2e_6{left:656px;bottom:440px;letter-spacing:-0.12px;word-spacing:-0.74px;}
#t2f_6{left:656px;bottom:418px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t2g_6{left:656px;bottom:376px;letter-spacing:0.07px;word-spacing:1.99px;}
#t2h_6{left:656px;bottom:349px;letter-spacing:-0.13px;word-spacing:0.11px;}
#t2i_6{left:656px;bottom:326px;letter-spacing:-0.09px;word-spacing:0.18px;}
#t2j_6{left:656px;bottom:304px;letter-spacing:-0.18px;word-spacing:-0.64px;}
#t2k_6{left:656px;bottom:281px;letter-spacing:-0.3px;}
#t2l_6{left:703px;bottom:288px;letter-spacing:-0.17px;}
#t2m_6{left:725px;bottom:281px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t2n_6{left:656px;bottom:258px;letter-spacing:-0.03px;word-spacing:-0.01px;}
#t2o_6{left:832px;bottom:258px;letter-spacing:-0.49px;}
#t2p_6{left:864px;bottom:258px;letter-spacing:-0.03px;word-spacing:-0.01px;}
#t2q_6{left:1045px;bottom:258px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t2r_6{left:656px;bottom:236px;letter-spacing:-0.09px;word-spacing:0.06px;}
#t2s_6{left:656px;bottom:198px;letter-spacing:-0.1px;word-spacing:0.07px;}
#t2t_6{left:656px;bottom:175px;letter-spacing:-0.11px;word-spacing:-0.42px;}
#t2u_6{left:656px;bottom:153px;letter-spacing:-0.17px;word-spacing:0.14px;}
#t2v_6{left:656px;bottom:130px;letter-spacing:-0.13px;word-spacing:0.11px;}
#t2w_6{left:656px;bottom:107px;letter-spacing:-0.19px;word-spacing:0.17px;}
#t2x_6{left:656px;bottom:85px;letter-spacing:-0.21px;word-spacing:0.18px;}
#t2y_6{left:656px;bottom:62px;letter-spacing:-0.32px;word-spacing:0.28px;}
#t2z_6{left:801px;bottom:70px;letter-spacing:-0.16px;}
#t30_6{left:844px;bottom:62px;letter-spacing:-0.16px;word-spacing:-1.06px;}
#t31_6{left:77px;bottom:889px;letter-spacing:0.18px;}

.s0_6{font-size:10px;font-family:ArialMT_5i;color:#000;}
.s1_6{font-size:6px;font-family:ArialMT_5i;color:#000;}
.s2_6{font-size:27px;font-family:Arial-BoldMT_58;color:#000;}
.s3_6{font-size:17px;font-family:Arial-BoldMT_58;color:#000;}
.s4_6{font-size:17px;font-family:ArialMT_5i;color:#000;}
.s5_6{font-size:17px;font-family:Arial-ItalicMT_5n;color:#000;}
.s6_6{font-size:11px;font-family:ArialMT_5i;color:#000;}
.s7_6{font-size:15px;font-family:Arial-BoldItalicMT_5d;color:#000;}
.s8_6{font-size:19px;font-family:Arial-BoldMT_58;color:#000;}
.s9_6{font-size:10px;font-family:NimbusSans-Regular_62;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts6" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_5d;
	src: url("fonts/Arial-BoldItalicMT_5d.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_58;
	src: url("fonts/Arial-BoldMT_58.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_5n;
	src: url("fonts/Arial-ItalicMT_5n.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5i;
	src: url("fonts/ArialMT_5i.woff") format("woff");
}

@font-face {
	font-family: NimbusSans-Regular_62;
	src: url("fonts/NimbusSans-Regular_62.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg6Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg6" style="-webkit-user-select: none;"><object width="1286" height="909" data="6/6.svg" type="image/svg+xml" id="pdf6" style="width:1286px; height:909px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_6" class="t s0_6">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_6" class="t s1_6">© </span>
<span id="t3_6" class="t s0_6">(NCCN </span>
<span id="t4_6" class="t s1_6">© </span>
<span id="t5_6" class="t s0_6">), All rights reserved. NCCN Guidelines </span>
<span id="t6_6" class="t s1_6">® </span>
<span id="t7_6" class="t s0_6">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_6" class="t s2_6">NCCN Guidelines Version 4.2024 </span>
<span id="t9_6" class="t s2_6">Head and Neck Cancers </span>
<span id="ta_6" class="t s3_6">MS-46 </span>
<span id="tb_6" class="t s4_6">NCCN Guidelines for Head and Neck Cancers). Surgery is also an option </span>
<span id="tc_6" class="t s4_6">for this patient population. For those patients whose disease persists after </span>
<span id="td_6" class="t s4_6">systemic therapy/RT or RT, surgical therapy is indicated (see </span><span id="te_6" class="t s5_6">Post </span>
<span id="tf_6" class="t s5_6">Systemic Therapy/RT or RT Neck Evaluation </span><span id="tg_6" class="t s4_6">in </span><span id="th_6" class="t s5_6">Follow-up </span>
<span id="ti_6" class="t s5_6">Recommendations </span><span id="tj_6" class="t s4_6">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="tk_6" class="t s4_6">Induction chemotherapy with management based on response is an option </span>
<span id="tl_6" class="t s4_6">for all but T1–2, N0 glottic and supraglottic cancers. Based on the long- </span>
<span id="tm_6" class="t s4_6">term update of RTOG 91-11, induction chemotherapy is an option for </span>
<span id="tn_6" class="t s4_6">patients who require (are amenable to) total laryngectomy. </span>
<span id="to_6" class="t s6_6">288 </span>
<span id="tp_6" class="t s4_6">After a </span>
<span id="tq_6" class="t s4_6">complete or partial response with induction chemotherapy for patients with </span>
<span id="tr_6" class="t s4_6">laryngeal cancer, RT alone is recommended (category 1) </span>
<span id="ts_6" class="t s6_6">288 </span>
<span id="tt_6" class="t s4_6">; systemic </span>
<span id="tu_6" class="t s4_6">therapy/RT is a category 2B recommendation after a partial </span>
<span id="tv_6" class="t s4_6">response </span>
<span id="tw_6" class="t s6_6">302,303,579 </span>
<span id="tx_6" class="t s4_6">(see </span><span id="ty_6" class="t s5_6">Cancer of the Glottic Larynx </span><span id="tz_6" class="t s4_6">and </span><span id="t10_6" class="t s5_6">Cancer of the </span>
<span id="t11_6" class="t s5_6">Supraglottic Larynx </span><span id="t12_6" class="t s4_6">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t13_6" class="t s4_6">For patients with glottic and supraglottic T4a tumors, the recommended </span>
<span id="t14_6" class="t s4_6">treatment approach is total laryngectomy with possible hemi- or total </span>
<span id="t15_6" class="t s4_6">thyroidectomy and appropriate neck dissection(s) followed by adjuvant </span>
<span id="t16_6" class="t s4_6">treatment (RT or systemic therapy/RT) </span>
<span id="t17_6" class="t s6_6">580 </span>
<span id="t18_6" class="t s4_6">(see </span><span id="t19_6" class="t s5_6">Cancer of the Glottic </span>
<span id="t1a_6" class="t s5_6">Larynx, </span><span id="t1b_6" class="t s5_6">Cancer of the Supraglottic Larynx, </span><span id="t1c_6" class="t s4_6">and </span><span id="t1d_6" class="t s5_6">Principles of Surgery </span><span id="t1e_6" class="t s4_6">in the </span>
<span id="t1f_6" class="t s4_6">NCCN Guidelines for Head and Neck Cancers). For selected patients with </span>
<span id="t1g_6" class="t s4_6">T4a tumors who decline surgery, the NCCN Panel recommends: 1) </span>
<span id="t1h_6" class="t s4_6">considering concurrent systemic therapy/RT; 2) clinical trials; or 3) </span>
<span id="t1i_6" class="t s4_6">induction chemotherapy with additional management based on </span>
<span id="t1j_6" class="t s4_6">response. </span>
<span id="t1k_6" class="t s6_6">288,294 </span>
<span id="t1l_6" class="t s7_6">Radiation Therapy Fractionation </span>
<span id="t1m_6" class="t s4_6">Fractionation for RT is discussed in the algorithm (see </span><span id="t1n_6" class="t s5_6">Cancer of the </span>
<span id="t1o_6" class="t s5_6">Glottic Larynx: Principles of Radiation Therapy </span><span id="t1p_6" class="t s4_6">and </span><span id="t1q_6" class="t s5_6">Cancer of the </span>
<span id="t1r_6" class="t s5_6">Supraglottic Larynx: Principles of Radiation Therapy </span><span id="t1s_6" class="t s4_6">in the NCCN </span>
<span id="t1t_6" class="t s4_6">Guidelines for Head and Neck Cancers). For patients with T1, N0 disease </span>
<span id="t1u_6" class="t s4_6">of the glottic larynx, an accelerated dosing schedule of 63 Gy (2.25 </span>
<span id="t1v_6" class="t s4_6">Gy/fraction) is preferred over conventional fractionation (66 Gy, 2.0 </span>
<span id="t1w_6" class="t s4_6">Gy/fraction), based on results of a prospective randomized trial showing </span>
<span id="t1x_6" class="t s4_6">that this accelerated dosing schedule was associated with better 5-year </span>
<span id="t1y_6" class="t s4_6">local control, compared to a conventional dosing schedule (92% vs. 77%, </span>
<span id="t1z_6" class="t s4_6">respectively; </span><span id="t20_6" class="t s5_6">P </span><span id="t21_6" class="t s4_6">= .004), in 180 patients with stage I cancer of the glottic </span>
<span id="t22_6" class="t s4_6">larynx. </span>
<span id="t23_6" class="t s6_6">164 </span>
<span id="t24_6" class="t s4_6">A dosing schedule of 50–52 Gy (3.12–3.28 Gy/fraction) may also </span>
<span id="t25_6" class="t s4_6">be considered for patients with comorbidities or travel logistics or who are </span>
<span id="t26_6" class="t s4_6">older adults. </span>
<span id="t27_6" class="t s6_6">581 </span>
<span id="t28_6" class="t s3_6">Follow-up/Surveillance </span>
<span id="t29_6" class="t s4_6">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="t2a_6" class="t s5_6">Follow-up Recommendations </span><span id="t2b_6" class="t s4_6">in the NCCN Guidelines for Head and Neck </span>
<span id="t2c_6" class="t s4_6">Cancers). Serial endoscopy is recommended during follow-up </span>
<span id="t2d_6" class="t s4_6">examinations and may be supplemented with high-resolution, advanced </span>
<span id="t2e_6" class="t s4_6">radiologic imaging because of the scarring, edema, and fibrosis that occur </span>
<span id="t2f_6" class="t s4_6">in the laryngeal tissues and neck after RT-based treatment. </span>
<span id="t2g_6" class="t s8_6">Paranasal Tumors (Maxillary and Ethmoid Sinus Tumors) </span>
<span id="t2h_6" class="t s4_6">Tumors of the paranasal sinuses are rare, and patients are often </span>
<span id="t2i_6" class="t s4_6">asymptomatic until late in the course of their disease. Tumors of the </span>
<span id="t2j_6" class="t s4_6">maxillary sinus are more common than those of the ethmoid sinus or nasal </span>
<span id="t2k_6" class="t s4_6">cavity. </span>
<span id="t2l_6" class="t s6_6">390 </span>
<span id="t2m_6" class="t s4_6">Workup is similar for ethmoid and maxillary sinus tumors (see </span>
<span id="t2n_6" class="t s5_6">Ethmoid Sinus Tumors </span><span id="t2o_6" class="t s4_6">and </span><span id="t2p_6" class="t s5_6">Maxillary Sinus Tumors </span><span id="t2q_6" class="t s4_6">in the NCCN </span>
<span id="t2r_6" class="t s4_6">Guidelines for Head and Neck Cancers). </span>
<span id="t2s_6" class="t s4_6">Although the most common histology for these tumors is squamous cell </span>
<span id="t2t_6" class="t s4_6">carcinoma, a variety of histologies have been reported including intestinal </span>
<span id="t2u_6" class="t s4_6">type adenocarcinoma, esthesioneuroblastoma (also known as olfactory </span>
<span id="t2v_6" class="t s4_6">neuroblastoma), minor salivary gland tumors, and undifferentiated </span>
<span id="t2w_6" class="t s4_6">carcinoma (eg, sinonasal undifferentiated carcinoma [SNUC], small cell </span>
<span id="t2x_6" class="t s4_6">carcinoma, midline NUT carcinoma, and sinonasal neuroendocrine </span>
<span id="t2y_6" class="t s4_6">carcinoma [SNEC]). </span>
<span id="t2z_6" class="t s6_6">582-586 </span>
<span id="t30_6" class="t s4_6">The defining features of esthesioneuroblastoma, </span>
<span id="t31_6" class="t s9_6">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
